Truveris

Join the Truveris team! This new role will support us at a pivotal time as we work to create a transparent pharmacy benefits ecosystem where data empowers better decision-making.

Are you happy with your pharmacy benefit manager contract? We are conducting a short, anonymous PBM satisfaction survey to capture how benefits consultants and employers view the performance of their current or past PBMs. Take the survey here: https://hubs.ly/Q03VdctD0

GLP-1s & TrumpRx: Given the most recent news around intended inclusion of discounted GLP-1s on TrumpRx, it's likely that PBMs will begin to revise their policies in anticipation of direct member purchases of medications instead of going through insurance. Read more about these updates and the latest recommendations from our PBM advisory team: https://hubs.ly/Q03TKxHD0

As specialty drug costs continue to climb, utilization management cannot be a “set-it-and-forget-it” process. Truveris’ Guide to Utilization Management in Pharmacy Contracts breaks down prior authorizations, step therapy, and quantity limits, and how to measure their impact The guide covers: Foundations of UM: Understand how effective programs balance clinical appropriateness, cost control, and member experience. Most Common UM Strategies: Learn more about prior authorizations, step therapy quantity limits, and when to best implement each. Strategic Evaluation Across the Contract Lifecycle: Consider aligning UM at procurement, assessing impact mid-contract, and revisiting terms at renewal. Access the guide here: https://hubs.ly/Q03RB5bY0

Today Truveris honors all who served and the families who stand behind them. Thank you for your service. #VeteransDay

How are you leveraging Utilization Management (UM) strategies? When structured thoughtfully and reviewed often, UM strategies balance three competing goals: clinical appropriateness, cost control, and member experience. Our new “Guide to Utilization Management in Pharmacy Contracts” breaks down prior authorizations, step therapy, and quantity limit strategies – and digs how employers should monitor these the pharmacy lifecycle. Download the guide to learn how the right UM approach can improve outcomes and control spend: https://hubs.ly/Q03RzXF_0

The recent Most Favored Nation (MFN) agreements between the Trump administration and manufacturers like Pfizer, AstraZeneca, and Merck apply only to Medicaid for now. However, if the Center for Medicare and Medicaid Services (CMS) shifts its pricing benchmarks, we could see ripple effects across commercial markets. To protect your pharmacy plan, make sure your contract has: • Defined inflation and rebate pass-through terms • Market check terms tied to external pricing shifts • Audit visibility to validate pricing streams as market conditions change Read our full update for a breakdown of what MFN could mean for future pharmacy benefit contracts: https://hubs.ly/Q03QKycL0

It’s always great to get together in person! Last month members of the Truveris product, operations, and marketplace team gathered in NYC ready to finish the year strong and prepare for 2026. Interested in joining our team? See our available roles on our LinkedIn page. #Truveris #pharmacybenefits #pharmacycostcontainment

Pharmaceutical tariffs could reshape pharmacy spend for self-funded employers. While the proposed 100% tariffs on internationally sourced branded drugs are still on hold, even a modest move on high-cost categories (like GLP-1s) could impact acquisition costs, formulary decisions, and supply stability. Several manufacturers have already announced multibillion-dollar U.S. investments to secure tariff exemptions, but the impact on plan budgets will depend on how policy definitions and timelines evolve. Steps employers can take today: • Ask your PBM how they’re assessing tariff exposure and adjusting formulary strategy • Review PBM contract terms for “market event” clauses • Monitor utilization trends in sensitive categories regularly Even before tariffs take effect, proactive claims oversight and clear PBM communication can help plans adapt as policy shifts unfold. Read more: https://hubs.ly/Q03QCQvT0

This week, Cigna announced a new pricing arrangement where drug discounts from manufacturers can be passed on directly to members at the point of sale, instead of sharing rebates with plan sponsors. Read more: https://hubs.ly/Q03QCwQ10